We are analyzing https://link.springer.com/article/10.1186/bcr3456.

Title:
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland | Breast Cancer Research
Description:
Introduction Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or tibolone and investigate pathways of cell proliferation in a postmenopausal primate model. Methods Ovariectomized female cynomolgus macaque monkeys were randomized into the following groups: placebo (Con), oral conjugated equine estrogens (CEE), CEE with medroxyprogesterone acetate (MPA) (CEE + MPA), and tibolone given at a low or high dose (Lo or Hi Tib). All study treatment doses represented human clinical dose equivalents and were administered in the diet over a period of 2 years. Results Treatment with CEE + MPA had the greatest effect on global mRNA profiles and markers of mammary gland proliferation compared to CEE or tibolone treatment. Changes in the transcriptional patterns resulting from the addition of MPA to CEE were related to increased growth factors and decreased estrogen receptor (ER) signaling. Specific genes induced by CEE + MPA treatment included key members of prolactin receptor (PRLR)/signal transducer and activator of transcription 5 (STAT5), epidermal growth factor receptor (EGFR), and receptor activator of nuclear factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL) pathways that were highly associated with breast tissue proliferation. In contrast, tibolone did not affect breast tissue proliferation but did elicit a mixed pattern of ER agonist activity. Conclusion Our findings indicate that estrogen + progestin therapy results in a distinct molecular profile compared to estrogen-alone or tibolone therapy, including upregulation of key growth factor targets associated with mammary carcinogenesis in mouse models. These changes may contribute to the promotional effects of estrogen + progestin therapy on breast cancer risk.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

rankl, breast, mammary, cee, expression, pubmed, article, cancer, rank, figure, mpa, google, scholar, cas, gland, proliferation, protein, cells, effects, mrna, control, analysis, estrogen, tibolone, group, genes, treatment, versus, factor, file, therapy, observed, postmenopausal, groups, growth, receptor, gene, epithelial, tissue, women, increased, usa, ihc, pathways, markers, progestin, signaling, additional, mouse, cell,

Topics {✒️}

tris-nacl-blocking buffer exhibit signaling cross-talk article download pdf hormone-induced breast proliferation target primer/probe sets li-ya huang goat anti-mouse igg hormone-dependent control contributing nonparametric kruskal-wallis test transforming growth factor-alpha global mrna profiles pr/ki-67 ihc incubation/staining progestogen-induced cell proliferation nf-kappab ligand induction progestin-driven mammary cancer parallel-arm design experiment progesterone-dominant luteal phase rank/opg mrna ratio lower-risk human populations rankl/opg mrna ratio rank/opg ratio expression basement matrix/basal layer progestogen-dependent breast proliferation heat-induced epitope retrieval rank/opg versus krt19 estrogen-progestin replacement therapy explore hormonal regulation rank/opg versus stat5a rankl/opg versus stat5a primary progestin-regulated pathways rank/opg mrna ratios hormone replacement therapy glyceraldehyde-3-phosphate dehydrogenase anti-progesterone receptor pgr menopausal hormone therapy long-term ept exposure estrogen + progestin therapy results postmenopausal hormone therapy cell proliferation included wake forest university primer/probe sets full access tgf-beta pathway activity molecular research center menopausal status [abstract] cee + mpa versus cee progestogen-dependent increases hormone-responsive genes human mammary gland received research funding

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
         description:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or tibolone and investigate pathways of cell proliferation in a postmenopausal primate model. Ovariectomized female cynomolgus macaque monkeys were randomized into the following groups: placebo (Con), oral conjugated equine estrogens (CEE), CEE with medroxyprogesterone acetate (MPA) (CEE + MPA), and tibolone given at a low or high dose (Lo or Hi Tib). All study treatment doses represented human clinical dose equivalents and were administered in the diet over a period of 2 years. Treatment with CEE + MPA had the greatest effect on global mRNA profiles and markers of mammary gland proliferation compared to CEE or tibolone treatment. Changes in the transcriptional patterns resulting from the addition of MPA to CEE were related to increased growth factors and decreased estrogen receptor (ER) signaling. Specific genes induced by CEE + MPA treatment included key members of prolactin receptor (PRLR)/signal transducer and activator of transcription 5 (STAT5), epidermal growth factor receptor (EGFR), and receptor activator of nuclear factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL) pathways that were highly associated with breast tissue proliferation. In contrast, tibolone did not affect breast tissue proliferation but did elicit a mixed pattern of ER agonist activity. Our findings indicate that estrogen + progestin therapy results in a distinct molecular profile compared to estrogen-alone or tibolone therapy, including upregulation of key growth factor targets associated with mammary carcinogenesis in mouse models. These changes may contribute to the promotional effects of estrogen + progestin therapy on breast cancer risk.
         datePublished:2013-08-12T00:00:00Z
         dateModified:2013-08-12T00:00:00Z
         pageStart:1
         pageEnd:16
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr3456
         keywords:
            Postmenopausal hormone therapy
            Estrogen
            Progestin
            Tibolone
            Breast cancer
            Gene expression
            RANKL
            Denosumab
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig7_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig8_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Charles E Wood
               affiliation:
                     name:Wake Forest University School of Medicine
                     address:
                        name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daniel Branstetter
               affiliation:
                     name:Amgen Inc
                     address:
                        name:Department of Pathology, Amgen Inc, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Allison P Jacob
               affiliation:
                     name:Therapeutic Innovation Unit (TIU), Amgen Inc
                     address:
                        name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J Mark Cline
               affiliation:
                     name:Wake Forest University School of Medicine
                     address:
                        name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas C Register
               affiliation:
                     name:Wake Forest University School of Medicine
                     address:
                        name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kathy Rohrbach
               affiliation:
                     name:Amgen Inc
                     address:
                        name:Department of Pathology, Amgen Inc, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Li-Ya Huang
               affiliation:
                     name:Amgen Inc
                     address:
                        name:Department of Pathology, Amgen Inc, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hermina Borgerink
               affiliation:
                     name:Wake Forest University School of Medicine
                     address:
                        name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William C Dougall
               affiliation:
                     name:Therapeutic Innovation Unit (TIU), Amgen Inc
                     address:
                        name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
      description:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or tibolone and investigate pathways of cell proliferation in a postmenopausal primate model. Ovariectomized female cynomolgus macaque monkeys were randomized into the following groups: placebo (Con), oral conjugated equine estrogens (CEE), CEE with medroxyprogesterone acetate (MPA) (CEE + MPA), and tibolone given at a low or high dose (Lo or Hi Tib). All study treatment doses represented human clinical dose equivalents and were administered in the diet over a period of 2 years. Treatment with CEE + MPA had the greatest effect on global mRNA profiles and markers of mammary gland proliferation compared to CEE or tibolone treatment. Changes in the transcriptional patterns resulting from the addition of MPA to CEE were related to increased growth factors and decreased estrogen receptor (ER) signaling. Specific genes induced by CEE + MPA treatment included key members of prolactin receptor (PRLR)/signal transducer and activator of transcription 5 (STAT5), epidermal growth factor receptor (EGFR), and receptor activator of nuclear factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL) pathways that were highly associated with breast tissue proliferation. In contrast, tibolone did not affect breast tissue proliferation but did elicit a mixed pattern of ER agonist activity. Our findings indicate that estrogen + progestin therapy results in a distinct molecular profile compared to estrogen-alone or tibolone therapy, including upregulation of key growth factor targets associated with mammary carcinogenesis in mouse models. These changes may contribute to the promotional effects of estrogen + progestin therapy on breast cancer risk.
      datePublished:2013-08-12T00:00:00Z
      dateModified:2013-08-12T00:00:00Z
      pageStart:1
      pageEnd:16
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr3456
      keywords:
         Postmenopausal hormone therapy
         Estrogen
         Progestin
         Tibolone
         Breast cancer
         Gene expression
         RANKL
         Denosumab
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig7_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr3456/MediaObjects/13058_2013_3258_Fig8_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Charles E Wood
            affiliation:
                  name:Wake Forest University School of Medicine
                  address:
                     name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daniel Branstetter
            affiliation:
                  name:Amgen Inc
                  address:
                     name:Department of Pathology, Amgen Inc, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Allison P Jacob
            affiliation:
                  name:Therapeutic Innovation Unit (TIU), Amgen Inc
                  address:
                     name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J Mark Cline
            affiliation:
                  name:Wake Forest University School of Medicine
                  address:
                     name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas C Register
            affiliation:
                  name:Wake Forest University School of Medicine
                  address:
                     name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kathy Rohrbach
            affiliation:
                  name:Amgen Inc
                  address:
                     name:Department of Pathology, Amgen Inc, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Li-Ya Huang
            affiliation:
                  name:Amgen Inc
                  address:
                     name:Department of Pathology, Amgen Inc, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hermina Borgerink
            affiliation:
                  name:Wake Forest University School of Medicine
                  address:
                     name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William C Dougall
            affiliation:
                  name:Therapeutic Innovation Unit (TIU), Amgen Inc
                  address:
                     name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:15
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Wake Forest University School of Medicine
      address:
         name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
         type:PostalAddress
      name:Amgen Inc
      address:
         name:Department of Pathology, Amgen Inc, Seattle, USA
         type:PostalAddress
      name:Therapeutic Innovation Unit (TIU), Amgen Inc
      address:
         name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
         type:PostalAddress
      name:Wake Forest University School of Medicine
      address:
         name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
         type:PostalAddress
      name:Wake Forest University School of Medicine
      address:
         name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
         type:PostalAddress
      name:Amgen Inc
      address:
         name:Department of Pathology, Amgen Inc, Seattle, USA
         type:PostalAddress
      name:Amgen Inc
      address:
         name:Department of Pathology, Amgen Inc, Seattle, USA
         type:PostalAddress
      name:Wake Forest University School of Medicine
      address:
         name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
         type:PostalAddress
      name:Therapeutic Innovation Unit (TIU), Amgen Inc
      address:
         name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Charles E Wood
      affiliation:
            name:Wake Forest University School of Medicine
            address:
               name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
               type:PostalAddress
            type:Organization
      name:Daniel Branstetter
      affiliation:
            name:Amgen Inc
            address:
               name:Department of Pathology, Amgen Inc, Seattle, USA
               type:PostalAddress
            type:Organization
      name:Allison P Jacob
      affiliation:
            name:Therapeutic Innovation Unit (TIU), Amgen Inc
            address:
               name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
               type:PostalAddress
            type:Organization
      name:J Mark Cline
      affiliation:
            name:Wake Forest University School of Medicine
            address:
               name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
               type:PostalAddress
            type:Organization
      name:Thomas C Register
      affiliation:
            name:Wake Forest University School of Medicine
            address:
               name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
               type:PostalAddress
            type:Organization
      name:Kathy Rohrbach
      affiliation:
            name:Amgen Inc
            address:
               name:Department of Pathology, Amgen Inc, Seattle, USA
               type:PostalAddress
            type:Organization
      name:Li-Ya Huang
      affiliation:
            name:Amgen Inc
            address:
               name:Department of Pathology, Amgen Inc, Seattle, USA
               type:PostalAddress
            type:Organization
      name:Hermina Borgerink
      affiliation:
            name:Wake Forest University School of Medicine
            address:
               name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
               type:PostalAddress
            type:Organization
      name:William C Dougall
      affiliation:
            name:Therapeutic Innovation Unit (TIU), Amgen Inc
            address:
               name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
      name:Department of Pathology, Amgen Inc, Seattle, USA
      name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA
      name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
      name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
      name:Department of Pathology, Amgen Inc, Seattle, USA
      name:Department of Pathology, Amgen Inc, Seattle, USA
      name:Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, USA
      name:Therapeutic Innovation Unit (TIU), Amgen Inc, Seattle, USA

External Links {🔗}(223)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.61s.

LINK . SPRINGER . COM {}